Whether you are employed as a scientist or as a business, conduct research anywhere in California, including cities where biotechnology and other medical sciences are studied or where research is conducted, especially in the areas around cities such as San Diego, Irvine, Orange County, Los Angeles, La Jolla, Riverside, Fullerton, San Francisco, Santa Barbara and other cities where there are universities or large research projects in the US and around the world, you know that patent laws and Patent licenses act as a barrier to health and biotechnology research and prevent scientific breakthroughs.
It doesn’t take a California patent attorney or a CA patent attorney to tell you how the world’s patent system today acts as a barrier to medical and biotech research that could solve many of today’s worst diseases and prevent innovative treatments, medicines and even new seeds for better harvests.
A new report came out after a seven-year study and confirmed what most patent licensing attorneys, medical researchers, and biotechnologists have known for years. The patent system in force throughout the world is broken and prevents advances in science.
Without a means to share information, patent lockup is causing delays in the development of advances in cancer drug treatments and in the development of new food crops.
The report by a Canada-based association cited HIV/AIDS drugs and cancer screening tests as examples of delayed medical advances.
What worries scientists is an increasingly empty medicine cabinet of new life-saving drugs that are critical not only for the developing world but also for industrialized nations to tackle the disease. New food crops that could help fight hunger are also being left behind.
And while stem cell researchers appear to be the most patenters, according to the report they are the least cooperative.
What happens is that “patent lockouts” act as barriers to research and advances in biotechnology that could advance cancer treatment, new drugs, and new crops.
When biotech companies rush to file a patent “fortress” around newly discovered genes, their competitors’ research is effectively stymied.
Another example given by scientists is work on breast cancer-causing genes in European countries that has been held up by a biotech company’s patents for specific genes in the US. They have effectively been denied access to such patents. evidence.
One recommendation in the report is that companies should be allowed to form “patent pools” where they can cross-license their patented technologies without losing royalties from their patents. It is also recommended that governments develop other public-private partnerships to conduct joint research.
The criticism of the current patent system is that it acts more as a barrier than an incentive for research and development of medical or biotechnological advances.
When a patent office grants dangerously broad patents, it can eliminate entirely new areas of research, such as in the field of nanotechnology.
As long as copyright and patent laws act as a barrier to others using and expanding a scientist’s research, the laws will prevent scientists from making advances that can benefit humanity. This lack of sharing prevents biotechnology from becoming the field it once promised.